Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupREPL +1.97%27 PB Ratio is 7.74 as of Aug. 13, 2026. GuruFocus rates REPL with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,220 Biotechnology companies, Replimune Group ranks worse than 80.41% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-13), Replimune Group's share price is $15.5399. Replimune Group's Book Value per Share for the quarter that ended in Mar. 2026 was $2.01. Hence, Replimune Group's PB Ratio of today is 7.74.
The historical rank and industry rank for Replimune Group's PB Ratio or its related term are showing as below:
REPL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 7.78
Current: 7.73
During the past 10 years, Replimune Group's highest PB Ratio was 7.78. The lowest was 0.00. And the median was 0.00.
REPL's PB Ratio is ranked worse than 80.41% of 1220
companies
in the Biotechnology industry
Industry Median: 2.905
vs REPL: 7.73
During the past 12 months, Replimune Group's average Book Value Per Share Growth Rate was -62.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -41.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Replimune Group was 25.90% per year. The lowest was -41.00% per year. And the median was -14.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Replimune Group PB Ratio Related Terms
Replimune Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Replimune Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Replimune Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Replimune Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Replimune Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Replimune Group (REPL) has a PB Ratio of 7.74 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #981 out of 1220 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Replimune Group's PB Ratio too high?
Replimune Group's current PB Ratio is 7.74. The Biotechnology industry median PB Ratio is 2.91. Replimune Group's value of 7.74 is 166.4% above this industry median. Based on the distribution chart, Replimune Group ranks #981 out of 1220 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's PB Ratio compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #981 out of 1220 companies for PB Ratio. This places Replimune Group in the lower half of its industry. The industry median PB Ratio is 2.91. Replimune Group's value of 7.74 is 166.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current PB Ratio of 7.74 is 166.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Replimune Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current PB Ratio is 7.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (REPL) has a current PB Ratio of 7.74. The current PB Ratio is 7.74 and 166.4% above the Biotechnology industry median of 2.91. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Replimune Group (REPL), the current PB Ratio is 7.74 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score
Get the complete analysis for REPL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REPL has been successfully added to your 
